Clinical Trial Update: Azacitidine and Quizartinib for the Treatment of Myelodysplastic Syndrome or Myelodysplastic/Myeloproliferative Neoplasm With FLT3 or CBL Mutations [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating the combination of azacitidine and quizartinib for patients with chronic myelomonocytic leukemia, myelodysplastic syndrome…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndrome
• Myelomonocytic Leukemia
• Myeloproliferative Neoplasm

Drugs mentioned

• Quizartinib (Quizartinib)
• VIDAZA (AZACITIDINE)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome | Phase 1, Phase 2 | Status: RECRUITING